The Discs Large (Dlg) protein is intimately involved in regulating cell polarity and cell proliferation, and is targeted by the high-risk Human Papillomavirus (HPV) E6 proteins for proteasome-mediated degradation. We show here that exposure of cells to osmotic shock induces the hyperphosphorylation of Dlg and its concomitant accumulation within the cell membrane at sites of cell contact, a process that requires an intact actin filament network. In addition, hyperphosphorylation of Dlg also renders it more susceptible to degradation induced by the HPV-18 E6 oncoprotein. Mutational analysis of Dlg identifies a region within the first 185 amino acids as being important for this, with phosphorylation on residue S158 being responsible for its enhanced targeting by the E6 oncoprotein. Using specific kinase inhibitors, we show that Jun N-terminal kinase (JNK) is in part responsible for this phosphorylation, and for the subsequent Dlg accumulation at sites of cell contact. These results further support the notion of a complex phosphorylation-dependent regulation of Dlg, both with respect to its precise cellular localisation and to its susceptibility to proteasomemediated degradation.
Introduction
Human Papillomaviruses (HPV) are the causative agents of a number of human cancers, the most important of which is cervical cancer (zur Hausen, 1996) . Two viral oncoproteins, E6 and E7, are responsible for inducing the malignancy, which is brought about by their interactions with key regulators of cell growth and proliferation (for reviews see Munger et al., 2001) . Recent studies using transgenic mice expressing the two viral proteins individually have begun to dissect the relative contributions of each viral protein to the oncogenic process. Thus, while E7 appears to be largely responsible for driving cell proliferation and the early stages of malignancy, E6 appears to be mainly responsible for the later, more malignant stages, of disease progression (Song et al., 1999 (Song et al., , 2000 .
A very large number of studies have been performed to elucidate the mechanism of action of the E6 oncoprotein, one of whose most important targets is the p53 tumour suppressor, which it targets for proteasome-mediated degradation (Thomas et al., 1999 for review). However, E6 proteins derived from the lowrisk virus types, which induce malignancy with only very low frequency, nonetheless also associate with p53 (Li and Coffino, 1996) , and a similar situation is also true for many other E6 target proteins. In contrast, a unique attribute of the high-risk E6 proteins, derived from HPV-16 or HPV-18, is their ability to interact with a subset of PDZ domain-containing substrate proteins via a short stretch of four amino acids in the extreme carboxy terminus of E6 (Kiyono et al., 1997; Lee et al., 1997) . This region is completely absent in E6 proteins from HPV types that are associated only with benign lesions, suggesting that this activity of E6 may be related to its ability to induce malignant progression. Indeed a number of studies would appear to support this hypothesis. Thus, an intact PDZ-binding motif was shown to be required for morphological transformation of human keratinocytes by E6 (Watson et al., 2003) , and recent studies in transgenic mice have shown that an E6 mutated within its PDZ binding site was greatly impaired in its ability to induce epithelial hyperplasia (Nguyen et al., 2003a, b) .
A number of different PDZ domain-containing proteins have been shown to be targets of the HPV-16 and HPV-18 E6 oncoproteins. These include members of the MAGI family, MUPP1, hScrib and Dlg (Kiyono et al., 1997; Lee et al., 1997; Glaunsinger et al., 2000; Lee et al., 2000; Nakagawa and Huibregtse, 2000; Thomas et al., 2002) . Although all of them appear to be involved in regulating signalling pathways from the cell membrane, most information is available concerning Dlg. In Drosophila, Dlg is classified as a tumour suppressor, regulating processes controlling cell polarity and proliferation (Woods et al., 1996; Bilder et al., 2000) . In mice, loss of Dlg function results in craniofacial abnormalities consistent with a breakdown in the normal control of cell polarity (Caruana and Bernstein, 2001 ). In addition, loss of Dlg or an altered pattern of expression is frequent in many tumours, particularly at the later stages of malignant progression (Watson et al., 2002; Cavatorta et al., 2004; Fuja et al., 2004) , and it is also a potent inhibitor of transformed cell growth (Massimi et al., 2004) , further supporting a role in cancer development. Although the HPV E6 protein can direct the degradation of Dlg at the 26S proteasome (Gardiol et al., 1999) , there is evidence to suggest that certain phosphorylated forms of Dlg are the preferred targets . Interestingly, recent studies have reported that Dlg is highly phosphorylated by the p38g MAPK in response to osmotic shock (Sabio et al., 2005) . Therefore, we were interested in investigating whether the osmotic shock-driven phosphorylation of Dlg could affect its susceptibility to E6-induced degradation.
Results

E6-induced degradation of Dlg is enhanced after osmotic shock
Recent studies have shown that Dlg is subject to phosphorylation by p38 MAPK following osmotic shock and that the phosphorylation sites lie within the amino terminal half of the protein (Sabio et al., 2005) . To investigate whether the osmotic shock-induced phosphorylation of Dlg could affect its susceptibility to E6-induced degradation, we first investigated the extent of Dlg phosphorylation that is induced by osmotic shock in a transient transfection assay. Human 293 cells were transfected with Dlg or with its mutant derivatives as depicted in Figure 1a , and after 24 h the cells were exposed to 0.3 M sorbitol for 1 h. After this time the cells were extracted and the pattern of Dlg expression was monitored by Western blot analysis with anti-HA antibody. The results obtained are shown in Figure 1b and demonstrate a clear upward shift in the mobility of the wild-type Dlg and the DSH3 mutant. However, none of the Dlg constructs that lack the first 185 amino acids of the protein exhibit this shift, suggesting that this region is required for phosphorylation-induced altered migration of Dlg following exposure to sorbitol. To verify that the more slowly migrating forms were indeed phosphorylated, the Western blot was repeated after the cell extracts had been incubated with l-phosphatase for 30 min. As can be seen from Figure 1c , the slower migrating forms of Dlg disappear upon phosphatase treatment, demonstrating that the mobility shift is a consequence of phosphorylation of the Dlg protein. Interestingly, the DNT mutant, which shows no altered mobility following sorbitol treatment, is nonetheless phosphorylated under normal conditions, suggesting that there are sites of phosphorylation on Dlg that are constitutively phosphorylated and which lie outside the first 185 amino acids. In order to further confirm that the slower migrating forms of Dlg were hyper-phosphorylated, cells were similarly transfected and subjected to osmotic shock. Subsequently, Dlg was immunoprecipitated using anti-HA antibody and then analysed by Western blotting with an antiphospho-serine/threonine-specific antibody. The results obtained in Figure 1d demonstrate that Dlg is weakly phosphorylated in untreated cells but that this increases significantly following sorbitol treatment. These results are also in agreement with previous studies (Sabio et al., 2005) .
To investigate the susceptibility of phosphorylated Dlg to E6-induced degradation, cells were transfected with Dlg plus increasing amounts of an HPV-18 E6 expression plasmid. After 24 h the cells were exposed to sorbitol for 1 h and residual Dlg was measured by Western blot analysis. The results obtained are shown in Figure 2a and demonstrate that the slower migrating, phosphorylated, form of Dlg is significantly more susceptible to E6-induced degradation than the faster, nonphosphorylated, form of the protein. To exclude the possibility that this might be due to an effect of the sorbitol on E6 activity, the assay was repeated with the DNT mutant of Dlg. As can be seen from Figure 2b there is no change in the efficiency with which E6 targets this mutant for degradation, irrespective of the presence of sorbitol. Previous studies had shown that Dlg could be phosphorylated at residues within this N-terminal region following osmotic shock (Sabio et al., 2005) . To investigate this further, we repeated the assay using two phosphorylation defective mutants of Dlg: S158A, which lies within this region, and S209A, which lies just outside it. Cells were transfected with the wild-type and mutant Dlg expression plasmids, together with increasing amounts of E6 expression plasmid. Following exposure to osmotic shock cells were harvested and the remaining Dlg was assessed by Western blot analysis using anti-GST antibodies. The results obtained are shown in Figure 2c and demonstrate that wild-type and the S209A mutant of Dlg are both susceptible to increased levels of E6-induced degradation following osmotic shock. In contrast, mutant S158A, while still susceptible to E6-induced degradation, is unaffected by the addition of sorbitol. These results demonstrate that phosphorylation on residue S158A of Dlg after osmotic shock treatment is responsible for increasing Dlg's susceptibility to E6-induced degradation.
Dlg accumulates at sites of cell contact after osmotic shock in an actin-dependent manner Having found that the sorbitol-induced phosphorylation of Dlg renders it more susceptible to E6-induced degradation in a transient transfection assay, we then proceed to investigate the effects of E6 upon Phosphorylation of the Dlg tumour suppressor protein P Massimi et al endogenous Dlg. For this experiment, HaCat keratinocytes were transfected with HA-tagged HPV-18 E6 and after 24 h they were incubated with sorbitol for 1 h. Cells were then fixed and stained for E6 and Dlg. The results obtained are shown in Figure 2d and demonstrate that transfection of HaCat cells with E6 results in a slight decrease in the level of Dlg found within the cell. In contrast, if the cells are exposed to sorbitol there is a dramatic reduction in Dlg levels, suggesting that E6 will also preferentially degrade endogenous Dlg following osmotic shock. An additional interesting observation to be made from this assay is the marked accumulation of Dlg within the cell membrane and at sites of cell contact upon osmotic shock of cells lacking E6. This suggests that the osmotic shock-induced phosphorylation of Dlg triggers a relocalisation of Dlg to the cell membrane in cells lacking E6.
To further characterise this relocalisation of Dlg we proceeded to investigate the rate with which this occurs following osmotic shock. HaCat cells were exposed to sorbitol for different periods of time and were then fixed and stained for Dlg. The results in Figure 3a demonstrate that there is an accumulation of Dlg within the cell membrane as little as 15 min after osmotic shock. Previous studies had suggested that movement of Dlg around the cell might be mediated by its ability to interact with the kinesin-like molecular motor GAKIN or Myosin VI (Hanada et al., 2000; Wu et al., 2002) . To investigate whether this movement of Dlg required microtubules, actin filaments or was simply a reflection of the degradation of nonmembrane-bound forms of the protein, the assay was repeated. However, this time cells were incubated with CBZ/LLnl to block the proteasome machinery, nocodazole to disrupt the microtubule network and cytochalasin B to disrupt the actin filament network. The results in Figure 3b show that CBZ/LLnl and nocodozole treatment have no effect on Dlg's recruitment to the cell membrane upon osmotic shock, indicating that neither proteasome-mediated degradation of Dlg nor microtubule transport are involved in Phosphorylation of the Dlg tumour suppressor protein P Massimi et al this process. However, there is an inhibition of Dlg staining at the cell membrane after cytochalasin B treatment, indicating that Dlg movement following osmotic shock most likely requires an intact actin filament network.
Dlg movement correlates with increased phosphorylation and accumulation within insoluble complexes
We were then interested in determining whether the relocalisation of Dlg in HaCat cells was coincident with an increased level of phosphorylation following osmotic shock. Cells were exposed to sorbitol for different periods, and the pattern of Dlg expression was monitored by Western blot analysis. The results obtained are shown in Figure 4a and show a change in the migration pattern of Dlg after 15 min' exposure to osmotic stress. Treatment of the cell extract with l-phosphatase ( Figure 4b ) further confirms that the change in mobility is due to phosphorylation, as does Western blot analysis using antiphospho-serine/threonine-specific antibodies on immunoprecipitated Dlg from HaCat cells (Figure 4c ). These results show that the phosphorylation of Dlg and its membrane relocalisation occur over a similar period of time following osmotic shock. We also included the HPV-positive As can be seen from Figure 4a , when CaSKi cells are exposed to osmotic shock there is only a modest increase in the hyperphosphorylated forms of Dlg and, interestingly, there is a general decrease in the total Dlg protein level. This result supports the transient transfection assays in indicating that phosphorylated Dlg is indeed more susceptible to E6-induced degradation.
To further investigate this apparent decrease in Dlg levels in CaSKi cells we repeated the immunofluorescent analysis of Dlg expression pre-and post-exposure to osmotic shock. The results in Figure 5a show that while there is some accumulation of Dlg at sites of cell contact, this is greatly diminished in comparison with that seen in HaCat cells, and there is also a very distinct absence of nuclear forms of the protein. Interestingly, preincubation with the proteasome inhibitors, CBZ/LLnL restores a significant amount of the nuclear/cytoplasmic pools of Dlg, as well as allowing increased membrane staining. For comparison, we also included the HPV-negative cervical tumour derived cell line C33I. The results in Figure 5b show that there is a low level of Dlg expression in this cell type; however, sorbitol exposure results in marked membrane accumulation of Dlg, and, unlike CaSKi cells, there is no significant decrease in nuclear/cytoplasmic forms of the protein and proteasome inhibition has no additional significant effects. These results further support the notion that hyperphosphorylated Dlg is indeed preferentially targeted by E6 for proteasome-mediated degradation.
To investigate this further, Western blot analysis of the endogenous Dlg in CaSKi and HaCat cells was performed following exposure to osmotic stress. The proteasome inhibitors CBZ/LLnl were also included to rescue any Dlg, which might be subject to proteasomemediated degradation. The samples were also divided such that both soluble and insoluble forms of Dlg could be analysed. The results obtained are shown in Figure 6 . In HaCat cells slower migrating forms of Dlg are readily detectable after osmotic shock and there is also a striking accumulation of Dlg within the insoluble fraction, further supporting a redistribution of Dlg within the cell. Interestingly, the presence or absence of proteasome inhibitors had minimal effects upon the levels of phosphorylated Dlg and upon its accumulation within the insoluble fraction. A very different situation was observed in CaSKi cells. The level of hyperphosphorylated Dlg detectable following exposure to osmotic shock was very low, as was its accumulation within the insoluble fraction. However, when proteasome inhibitors were added to the cells there was a rescue of hyperphosphorylated forms of Dlg, as well as an increase in the amount of Dlg accumulating within the insoluble fraction of the cell. When HPV-negative cervical tumour derived C33-I cells were similarly analysed (Figure 6c) , very low levels of Dlg expression were observed which is consistent with previous observations . However, an accumulation of slower migrating forms could be seen after osmotic shock and, interestingly, these forms of Dlg were unaffected by proteasome inhibition. HaCat cell extracts were also exposed to 30 min incubation with lphosphatase to demonstrate that the slower migrating species are phosphorylated forms of Dlg (note the disappearance of bracketed forms). The multiple protein bands remaining in the phosphatasetreated extracts correspond to different isomeric forms of Dlg (Lue et al., 1994) . (c) Western blot analysis of phospho-serine/threoninespecific forms of Dlg in HaCat cells. Cells were exposed to osmotic shock, as indicated, and extracts immunoprecipitated with either preimmune (P.I) or anti-Dlg antibody (a-Dlg). Complexes were then analysed by Western blotting with antiphospho-specific antibody (a-MPM2). Note the increased signal of slower migrating forms of Dlg (bracketed) following sorbitol treatment. Left hand panel shows Western blot of input endogenous Dlg.
Phosphorylation of the Dlg tumour suppressor protein P Massimi et al
Phosphorylation of Dlg by Jun N-terminal kinase contributes to its osmotic stress-induced relocalisation Previous studies had shown that one of the major kinases responsible for phosphorylating Dlg upon osmotic shock was the p38g MAPK (Sabio et al., 2005) . To investigate which kinases are responsible for phosphorylating Dlg in CaSKi cells, and thereby rendering it susceptible to E6-induced degradation, we repeated the Western blot analysis and, as well as including CBZ/LLnl so that phosphorylated Dlg could be visualised, we also preincubated the cells with specific inhibitors of p38MAPKa and b, JNK and ERK1/2. The results obtained are shown in Figure 7 . Once again, slower migrating forms of Dlg are detectable following osmotic shock if the proteasome inhibitors are present. Interestingly however, some of these slower forms of Dlg are greatly diminished following inhibition of JNK. In contrast, there is no significant change in cells treated with inhibitors of ERK1/2 or p38a and b. Therefore these results suggest that, in addition to p38g (Sabio et al. 2005) , Dlg can also be phosphorylated by JNK in response to osmotic shock.
Finally, we were interested in determining whether inhibition of kinase activity could alter the redistribution of Dlg to the cell membrane after exposure to sorbitol. To do this, HaCat cells were preincubated with the different kinase inhibitors and, following osmotic shock, the cells were fixed and stained for Dlg expression. The results in Figure 8 show that treatment with p38 and ERK1/2 inhibitors has minimal effect upon the relocalisation of Dlg to the cell membrane. In contrast, treatment with JNK inhibitors completely blocks Dlg relocalisation. These results demonstrate that the osmotic shock-induced phosphorylation of Dlg by JNK targets Dlg to the cell membrane. Phosphorylation of the Dlg tumour suppressor protein P Massimi et al
Discussion
The Dlg tumour suppressor is a key regulator of diverse processes including cell polarity control, cell proliferation and cell attachment Woods et al., 1996; Bilder et al., 2000) . In addition, recent studies, where exposure to osmotic shock induced an increase in p38g-induced phosphorylation of Dlg (Sabio et al., 2005) , have suggested that it may also have a role in the cells' response to changes in the extracellular environment. We show here that the osmotic shock-induced phosphorylation of Dlg results in its rapid accumulation at sites of cell contact, suggesting that release of Dlg from the cytoskeleton may help to maintain cell contacts under conditions of osmotic stress. Interestingly, we also found that the HPV-16 and HPV-18 E6 oncoproteins preferentially targeted these phosphorylated forms of Dlg for proteasome-mediated degradation. This supports previous studies suggesting that E6 preferentially degrades discrete cellular pools of Dlg (Massimi et al., 2004) , and implies that only certain functions of Dlg are detrimental to the viral life cycle, and also, presumably, to the development of malignancy. Mutational analysis of Dlg identified a region within the first 185 amino acids as being important for its sorbitol-induced phosphorylation and for its enhanced susceptibility to E6-induced degradation. It is interesting to note that previous studies had also highlighted the importance of this region for E6-induced degradation, even though it lies well away from the E6 binding site within PDZ domain 2 (Gardiol et al., 2002) . Previous studies had identified four residues on Dlg that were phosphorylated following exposure to sorbitol, two within the amino-terminal domain at residues 158 and 209, while the other two were located at residues 431 and 442 (Sabio et al., 2005) . Interestingly, in our analysis, we saw no significant increase in phosphorylation-induced altered migration of the DNT truncation of Dlg (which lacks the first phosphorylation site), suggesting that phosphorylation of Dlg within this region is responsible for its slower migration. The DNT mutation was nonetheless constitutively phosphorylated, suggesting the existence of other, as yet unidentified, phosphorylation sites within the body of Dlg. These studies would CaSKi cells were exposed to 0.3 M sorbitol (Sorb), and subject to proteasome inhibition (CBZ), as indicated. Cells were also exposed to specific inhibitors of JNK, p38 and ERK1/2 as indicated. After 1 h, the cells were extracted and Dlg analysed by Western blotting. Note that the bracketed slower migrating forms of Dlg are diminished in cells treated with a JNK inhibitor.
Phosphorylation of the Dlg tumour suppressor protein P Massimi et al also suggest that the major site required for enhanced E6 targeting lies at residue S158. Indeed using Dlg mutants that are defective for phosphorylation at residues S158 and S209 confirmed this, with S209A behaving like wildtype Dlg and S158A not being subject to increased degradation following osmotic shock. Although we did not assess the role of p38g in phosphorylating Dlg in HaCat keratinocytes or in cervical tumour-derived cells, it is nonetheless clear that JNK would also appear to be a significant player. Thus, inhibition of ERK1/2 had no effect upon sorbitol-induced phosphorylation of Dlg, and inhibition of p38a/b also had minimal effect. However, inhibition of JNK resulted in a significant decrease in the levels of hyperphosphorylated forms of Dlg, although in no case was phosphorylation completely abolished, consistent with there being multiple kinase contributors to the sorbitol-induced phosphorylation of Dlg (Sabio et al., 2005) .
A particularly intriguing observation from these studies is the accumulation of Dlg at sites of cell contact following exposure to sorbitol. This seems to follow the temporal pattern of phosphorylation very closely, and it is also disrupted upon inhibition of JNK, suggesting that this relocalisation is indeed driven by JNK-induced phosphorylation of Dlg. Relocalisation also appears to require an active transport mechanism, most likely involving actin filaments, since the movement of Dlg was dramatically reduced following exposure of the cells to cytochalasin B. This is particularly intriguing since Dlg has been reported to interact with myosin VI which also moves along actin filaments (Wu et al., 2002) . However, this is a minus-end directed motor (Buss et al., 2002) , so it seems probable that another, plus-end directed, myosin would be involved in the osmotic stress-induced movement of Dlg. Microtubules, on the other hand, would not appear to be required since nocodazole had no significant effect upon Dlg relocalisation. Thus, while phosphorylation has been previously shown to effect the release of Dlg from GKAP and the cytoskeleton (Sabio et al., 2005) , we, on the other hand, observe here a rapid accumulation of Dlg within the cell membrane, and a marked shift from a readily extractable form of the protein to a form of Dlg that is resistant to low salt extraction, consistent with its forming high molecular weight complexes with membrane-associated proteins.
At present the reason for targeting Dlg to the cell membrane as a stress response is still unclear, as is the reason why these phosphorylated forms of Dlg are more readily degraded by E6. However, it is possible that in the latter case it is simply a reflection of accessibility. Thus, nonphosphorylated Dlg is linked to the cytoskeleton and cannot be accessed by E6. Following phosphorylation, Dlg is released and begins its journey to the cell membrane; en route it is accessible to the HPV E6 protein and is consequently targeted for proteasomemediated degradation. Once at the membrane, it seems most likely that Dlg's function would then be to aid the cell in responding to the changes in the extracellular environment by forming multiprotein complexes whose functions probably contribute to maintaining membrane integrity and cell-cell contact. These studies provide further evidence of a highly complex pattern of regulation of the Dlg tumour suppressor, and of a multifunctional role for the protein in diverse cellular compartments and pathways.
Materials and methods
Cell culture and transfections
The immortalised skin keratinocytes HaCat, the HPV-16-positive CaSKi, and the HPV-negative C33I and HEK293 cells were all maintained in DMEM supplemented with 10% foetal calf serum. Cells were transfected using standard calcium phosphate precipitation. For sorbitol treatment, the cells were grown overnight and exposed to 0.3 M sorbitol for the times indicated in the text. Where kinase and proteasome inhibitors or nocadozole and cytochalasin B were used, the cells were preincubated with the respective inhibitor 1 h before the addition of sorbitol and then incubated with sorbitol for a further hour. The proteasome inhibitors CBZLeu-Leu-Leu-al (CBZ, Sigma, Milano, Italy) and N-acetylLeu-Leu-norleucinal (LLnL, Sigma) were used at a final concentration of 50 mm. The ERK1/2 inhibitor (PD98059) was used at a concentration of 10 mM, the p38a/b inhibitor (SB203580) was used at a concentration of 20 mM and the JNK inhibitor (SP600125) was used at a concentration of 10 mM. Nocodazole was used at a concentration of 2 mg/ml and cytochalasin B was used at a concentration of 50 mM. In all the experiments where proteasome and/or kinase inhibitors were used, the control untreated cells were incubated with DMSO.
Plasmid DNA
The wild-type HA-tagged Dlg expression plasmid and mutant derivatives have been described previously (Gardiol et al., 2002; Sabio et al., 2005) , as has the HA-tagged HPV-18 E6 expression plasmid .
Western blotting
Cells were extracted in a solution of 50 mM Hepes pH 7.0, 250 mM NaCl, 0.1% NP40 and 1% aprotinin. Extracts were clarified by centrifugation at 13 000 r.p.m. for 2 min and were then divided into soluble (supernatant) and insoluble fractions (pellet), as indicated in the text. Where extracts were treated with l-phosphatase, they were incubated with 1000U lphosphatase (New England Biolabs, Milano, Italy) for 30 min at 301C. Protein concentrations were determined using the Bio-Rad Protein Assay System and equal amounts (100 mg) were separated on 7.5% SDS-PAGE and transferred to nitrocellulose membrane. Endogenous Dlg was detected using anti-Dlg monoclonal antibody (2D11, Santa Cruz, Heidelberg, Germany) and HA-tagged Dlg was detected using anti-HA monoclonal antibody (Roche, Monza, Italy). Western blots were developed using the Amersham, (Milano, Italy) ECL System according to the manufacturer's instructions. For antiphospho-serine/threonine assays, HA-tagged Dlg was first immunoprecipitated using anti-HA-linked agarose beads (Sigma), while endogenous Dlg was immunoprecipitated using anti-Dlg monoclonal antibody (2D11, Santa Cruz). Western blots were then probed with an antiphosphoSerine/Threonine-specific monoclonal antibody according to the manufacturer's instructions (MPM-2; Upstate, Milano, Italy).
Immunofluorescence
After the relevant treatment the cells were washed in PBS and fixed in 3% paraformaldehyde in PBS followed by 5 min in 0.1% Triton-PBS. The cells were then stained with anti-Dlg monoclonal antibody (2D11, Santa Cruz) and visualised with FITC-conjugated secondary antibody (Molecular Probes, Milano, Italy). Where HA-tagged E6 was included, anti-HA antibody (Roche) was used followed by RITC-conjugated secondary antibody (Molecular Probes).
